Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | 2025-10-16 22:25:45 | 83.52 | -0.4 | -0.48 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRK | 0000310158 | Merck & Co., Inc. | US58933Y1055 | — | 221918501 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | NJ | 126 EAST LINCOLN AVENUE | RAHWAY | NJ | 07065 | UNITED STATES | US | 908-740-4000 | 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065 | 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065 | Merck & Co. Inc. | Pharmaceuticals | 1891 | Robert M. Davis | 75,000 | http://merck.com | 313,799,000,000 | 3,577,103,522 | 2,497,783,211 | Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue. | 2025-10-10 19:02:37 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 313,799,000,000 | 20,870,000,000 | 7.1246 | 2,526,036,240 | -6,607,632 | -0.2609 |
| 2023 | 292,929,000,000 | 62,109,000,000 | 26.908 | 2,532,643,872 | -5,948,595 | -0.2343 |
| 2022 | 230,820,000,000 | 33,950,000,000 | 17.2449 | 2,538,592,467 | 10,858,861 | 0.4296 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Richard R. Deluca, Jr. | President, Executive Vice President | 2024 | 958,747 | 0 | 5,699,835 | 1,096,680 | 114,511 | 9,098,531 |
| Betty Larson | Chief Human Resources Officer, Executive Vice President | 2024 | 604,396 | 725,000 | 6,635,712 | 685,246 | 280,323 | 11,257,796 |
| Robert M. Davis | Chairman, President | 2024 | 1,623,874 | 0 | 13,077,541 | 2,761,650 | 561,112 | 23,186,064 |
| Caroline Litchfield | Chief Financial Officer, Executive Vice President | 2024 | 1,166,044 | 0 | 3,585,716 | 1,333,800 | 147,210 | 7,507,778 |
| Dean Li | President, Executive Vice President | 2024 | 1,451,077 | 0 | 4,724,760 | 1,659,840 | 170,183 | 10,086,332 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 75,000 |
| 2023 | 72,000 |
| 2022 | 69,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 64,168,000,000 | 60,115,000,000 | 59,283,000,000 |
| Cost Of Revenue | 15,193,000,000 | 16,126,000,000 | 17,411,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 17,938,000,000 | 30,531,000,000 | 13,548,000,000 |
| General And Administrative Expenses | 10,816,000,000 | 10,504,000,000 | 10,042,000,000 |
| Operating Expenses | — | — | — |
| Operating Income | — | — | — |
| Net Income | 17,117,000,000 | 365,000,000 | 14,519,000,000 |
| Earnings Per Share Basic | 6.76 | 0.14 | 5.73 |
| Earnings Per Share Diluted | 6.74 | 0.14 | 5.71 |
| Weighted Average Shares Outstanding Basic | 2,532,000,000 | 2,537,000,000 | 2,532,000,000 |
| Weighted Average Shares Outstanding Diluted | 2,541,000,000 | 2,547,000,000 | 2,542,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 13,242,000,000 | 6,841,000,000 | 12,694,000,000 |
| Marketable Securities Current | 447,000,000 | 252,000,000 | 498,000,000 |
| Accounts Receivable | 2,100,000,000 | 3,000,000,000 | 2,500,000,000 |
| Inventories | 6,109,000,000 | 6,358,000,000 | 5,911,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 8,706,000,000 | 8,368,000,000 | 7,169,000,000 |
| Total Assets Current | 38,782,000,000 | 32,168,000,000 | 35,722,000,000 |
| Marketable Securities Non Current | 463,000,000 | 252,000,000 | 1,015,000,000 |
| Property Plant And Equipment | 23,779,000,000 | 23,051,000,000 | 21,422,000,000 |
| Other Assets Non Current | 16,044,000,000 | 11,996,000,000 | 68,000,000 |
| Total Assets Non Current | 78,324,000,000 | 74,507,000,000 | 73,438,000,000 |
| Total Assets | 117,106,000,000 | 106,675,000,000 | 109,160,000,000 |
| Accounts Payable | 4,079,000,000 | 3,922,000,000 | 4,264,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 2,649,000,000 | 1,372,000,000 | 1,946,000,000 |
| Other Liabilities Current | 15,694,000,000 | 15,766,000,000 | 14,159,000,000 |
| Total Liabilities Current | 28,420,000,000 | 25,694,000,000 | 24,239,000,000 |
| Long Term Debt | 34,462,000,000 | 33,683,000,000 | 28,745,000,000 |
| Other Liabilities Non Current | 6,465,000,000 | 8,792,000,000 | 8,323,000,000 |
| Total Liabilities Non Current | 0 | 600,000,000 | 600,000,000 |
| Total Liabilities | 100,000,000 | 250,000,000 | 600,000,000 |
| Common Stock | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 |
| Retained Earnings | 63,069,000,000 | 53,895,000,000 | 61,081,000,000 |
| Accumulated Other Comprehensive Income | -4,945,000,000 | -5,161,000,000 | -4,768,000,000 |
| Total Shareholders Equity | 46,313,000,000 | 37,581,000,000 | 45,991,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,395,000,000 | 2,044,000,000 | 2,085,000,000 |
| Share Based Compensation Expense | 761,000,000 | 645,000,000 | 541,000,000 |
| Other Non Cash Income Expense | -510,000,000 | -355,000,000 | -1,301,000,000 |
| Change In Accounts Receivable | 244,000,000 | 1,148,000,000 | 644,000,000 |
| Change In Inventories | 835,000,000 | 816,000,000 | 161,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 182,000,000 | -380,000,000 | -289,000,000 |
| Change In Other Liabilities | -49,000,000 | 456,000,000 | -545,000,000 |
| Cash From Operating Activities | 21,468,000,000 | 13,006,000,000 | 19,095,000,000 |
| Purchases Of Marketable Securities | 519,000,000 | 955,000,000 | 1,204,000,000 |
| Sales Of Marketable Securities | — | — | 721,000,000 |
| Acquisition Of Property Plant And Equipment | 3,372,000,000 | 3,863,000,000 | 4,388,000,000 |
| Acquisition Of Business | 746,000,000 | 0 | 121,000,000 |
| Other Investing Activities | 127,000,000 | 36,000,000 | -32,000,000 |
| Cash From Investing Activities | -7,734,000,000 | 0 | 0 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 7,943,000,000 | 7,551,000,000 | 7,134,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 1,306,000,000 | 1,346,000,000 | 0 |
| Issuance Of Long Term Debt | — | 5,939,000,000 | 0 |
| Repayment Of Long Term Debt | 1,290,000,000 | 1,755,000,000 | 2,251,000,000 |
| Other Financing Activities | -372,000,000 | -328,000,000 | -240,000,000 |
| Cash From Financing Activities | -7,032,000,000 | -4,810,000,000 | -9,119,000,000 |
| Change In Cash | 6,409,000,000 | -5,864,000,000 | 4,606,000,000 |
| Cash At End Of Period | 13,242,000,000 | 6,841,000,000 | 12,694,000,000 |
| Income Taxes Paid | 3,928,000,000 | 4,338,000,000 | 3,200,000,000 |
| Interest Paid | 1,300,000,000 | 1,100,000,000 | 937,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 6.76 | 0.14 | 5.73 |
| Price To Earnings Ratio | 14.716 | 778.7143 | 19.363 |
| Earnings Growth Rate | 4,728.5714 | -97.5567 | 11.0465 |
| Price Earnings To Growth Ratio | 0.0031 | -7.9822 | 1.7529 |
| Book Value Per Share | 46.2109 | 41.9492 | 42.8752 |
| Price To Book Ratio | 2.1527 | 2.5989 | 2.5877 |
| Ebitda | 24,711,000,000 | 7,893,000,000 | 20,766,000,000 |
| Enterprise Value | 275,752,360,000 | 304,797,740,000 | 298,922,400,000 |
| Dividend Yield | 0.0315 | 0.0273 | 0.0254 |
| Dividend Payout Ratio | 0.464 | 20.6877 | 0.4914 |
| Debt To Equity Ratio | 0.8013 | 0.9328 | 0.6673 |
| Capital Expenditures | 3,123,000,000 | 3,673,000,000 | 4,228,000,000 |
| Free Cash Flow | 18,345,000,000 | 9,333,000,000 | 14,867,000,000 |
| Return On Equity | 0.3696 | 0.0097 | 0.3157 |
| One Year Beta | 0.2207 | 0.2542 | 0.2886 |
| Three Year Beta | 0.2603 | 0.2723 | 0.5278 |
| Five Year Beta | 0.4822 | 0.5147 | 0.5548 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Coe Mary Ellen | Director | 2025-09-30 | 357 | A | 28,684 |
| GLOCER THOMAS H | Director | 2025-09-30 | 580 | A | 105,645 |
| Seidman Christine E | Director | 2025-09-30 | 96 | A | 18,775 |
| Guindo Chirfi | Chief Marketing Officer | 2025-08-04 | 36,903 | A | 107,408 |
| Guindo Chirfi | Chief Marketing Officer | 2025-08-04 | 18,175 | D | 89,233 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H Tuberville | Senator | 2023-11-16 | Sale (Full) | 2023-10-16 | Joint | $1,001 - $15,000 |
| John P Ricketts | Senator | 2023-10-20 | Sale (Full) | 2023-09-21 | Spouse | $50,001 - $100,000 |
| Thomas H Tuberville | Senator | 2022-04-08 | Purchase | 2022-03-30 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2021-07-23 | Sale (Full) | 2021-03-29 | Joint | $1,001 - $15,000 |
| David A Perdue , Jr | Senator | 2021-05-02 | Sale (Full) | 2020-04-14 | Joint | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
| Sheri Biggs | 2025-10-05 | SC03 | Sale | 2025-03-19 | Spouse | $15,001 - $50,000 |
| Valerie Hoyle | 2025-09-12 | OR04 | Purchase | 2024-10-29 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-09-12 | MI09 | Sale | 2025-08-04 | Spouse | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-09-12 | CA31 | Purchase | 2025-08-05 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Bill Few Associates, Inc. | 2025-09-30 | 1,085,884 | 12,938 | 83.9298 |
| WILLNER & HELLER, LLC | 2025-09-30 | 648,103 | 7,722 | 83.9294 |
| Carnegie Investment Counsel | 2025-09-30 | 6,283,483 | 74,866 | 83.9297 |
| 180 WEALTH ADVISORS, LLC | 2025-09-30 | 3,439,981 | 40,986 | 83.9306 |
| Castle Rock Wealth Management, LLC | 2025-09-30 | 2,331,121 | 26,325 | 88.5516 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Dearborn Partners Rising Dividend Fund - Class I Shares | DRDIX | 77,920 | 6,554,630.4 | 1.0383 |
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Dearborn Partners Rising Dividend Fund - Class C Shares | DRDCX | 77,920 | 6,554,630.4 | 1.0383 |
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Dearborn Partners Rising Dividend Fund - Class A Shares | DRDAX | 77,920 | 6,554,630.4 | 1.0383 |
| Pacer Funds Trust | 2025-07-31 | Pacer US Export Leaders ETF | PEXL | 3,986 | 311,386.32 | 0.8923 |
| Pacer Funds Trust | 2025-07-31 | Pacer US Large Cap Cash Cows Growth Leaders ETF | COWG | 108,813 | 8,500,471.56 | 0.3656 |